19:38:41 Europe / Stockholm

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande

Kalender

2024-08-30 Kvartalsrapport 2024-Q2
2024-04-12 Ordinarie utdelning TRMED 0.00 NOK
2024-04-11 Årsstämma 2024
2024-02-28 Bokslutskommuniké 2023
2023-08-31 Kvartalsrapport 2023-Q2
2023-04-27 Ordinarie utdelning TRMED 0.00 NOK
2023-04-26 Årsstämma 2023
2023-02-28 Bokslutskommuniké 2022
2022-08-31 Kvartalsrapport 2022-Q2
2022-04-29 Ordinarie utdelning TRMED 0.00 NOK
2022-04-28 Årsstämma 2022
2022-03-01 Bokslutskommuniké 2021
2021-11-18 15-10 2021-Q3
2021-08-26 Kvartalsrapport 2021-Q2
2021-05-26 Kvartalsrapport 2021-Q1
2021-04-28 Årsstämma 2021
2021-04-16 Ordinarie utdelning TRMED 0.00 NOK
2021-03-22 Extra Bolagsstämma 2021
2021-02-18 Bokslutskommuniké 2020
2020-11-19 Kvartalsrapport 2020-Q3
2020-10-21 Extra Bolagsstämma 2020
2020-08-27 Kvartalsrapport 2020-Q2
2020-06-11 Ordinarie utdelning TRMED 0.00 NOK
2020-06-10 Årsstämma 2020
2020-05-26 Kvartalsrapport 2020-Q1
2020-02-27 Bokslutskommuniké 2019
2019-11-19 Kvartalsrapport 2019-Q3
2019-08-22 Kvartalsrapport 2019-Q2
2019-05-23 Kvartalsrapport 2019-Q1
2019-04-26 Ordinarie utdelning TRMED 0.00 NOK
2019-04-25 Årsstämma 2019
2019-02-18 Extra Bolagsstämma 2019
2018-08-22 Kvartalsrapport 2018-Q2
2018-05-31 Ordinarie utdelning TRMED 0.00 NOK
2018-05-30 Kvartalsrapport 2018-Q1
2018-05-30 Årsstämma 2018
2018-02-27 Bokslutskommuniké 2017
2017-12-20 Extra Bolagsstämma 2017
2017-11-22 Kvartalsrapport 2017-Q3
2017-08-23 Kvartalsrapport 2017-Q2
2017-05-26 Ordinarie utdelning TRMED 0.00 NOK
2017-05-24 Kvartalsrapport 2017-Q1
2017-05-24 Årsstämma 2017
2017-02-28 Bokslutskommuniké 2016
2016-11-23 Kvartalsrapport 2016-Q3
2016-10-12 Extra Bolagsstämma 2016
2016-08-24 Kvartalsrapport 2016-Q2
2016-05-31 Kapitalmarknadsdag 2016
2016-05-20 Ordinarie utdelning TRMED 0.00 NOK
2016-05-19 Årsstämma 2016
2016-05-19 Kvartalsrapport 2016-Q1
2016-02-26 Bokslutskommuniké 2015
2015-11-17 Kapitalmarknadsdag 2015
2015-10-21 Kvartalsrapport 2015-Q3
2015-08-26 Kvartalsrapport 2015-Q2
2015-05-27 Kvartalsrapport 2015-Q1
2015-03-09 Årsstämma 2015
2014-11-12 Extra Bolagsstämma 2014

Beskrivning

LandNorge
ListaOB Match
SektorHälsovård
IndustriLäkemedel & Handel
Thor Medical är ett läkemedelsbolag. Bolaget specialiserar sig inom utveckling av antikroppsläkemedel för behandling utav hematologisk cancer. Störst specialisering återfinns inom precisionsterapi som används i den kliniska fasen. Övriga sjukdomar som behandlas är non-hodgkins lymfom (NHL). Bolaget grundades under 2009 och har sitt huvudkontor i Oslo, Norge.
2019-12-04 07:00:15
Oslo, Norway, 4 December 2019

Nordic Nanovector ASA (OSE: NANO) announces that new data from preclinical
studies investigating the effect of Betalutin® ([177]Lu-lilotomab satetraxetan)
on non-Hodgkin's lymphoma (NHL) cell lines will be presented in a poster at the
61[st] American Society of Hematology (ASH) Annual Meeting & Exposition (7-10
December 2019 in Orlando, FL, USA).

The ongoing research programme aims to investigate resistance mechanisms that
enable NHL cells to survive Betalutin® treatment and to identify molecules that,
when used in combination with Betalutin®, could overcome that resistance.  The
findings of this research could direct future programmes designed to expand the
use of Betalutin®-based therapies in NHL patients.

The research being presented at ASH builds on data previously presented (at the
European Haematology Association annual meeting in June 2018) describing how a
screen of more than 50 different NHL cell lines identified some cell lines that
were resistant to Betalutin®. Two resistant cell lines were aggressive diffuse
large B-cell lymphoma (DLBCL) cell lines (the double-hit/double-expressor ABC
-DLBCL cell lines RIVA and U2932).

The new poster reports how these two aggressive DLBCL cell lines have been used
in a new screen where Betalutin® has been combined with 384 different anti
-cancer drugs to identify the Betalutin®/drug combinations that could
potentially contribute to reverting resistance.

Jostein Dahle, Chief Scientific Officer of Nordic Nanovector, said: "Our ongoing
research programmes and collaborations continue to help us understand how NHL
cells react to Betalutin® treatment. Understanding the mechanisms of resistance
to Betalutin®, and how to overcome them, is crucial for being able to deliver
optimal treatment to patients with difficult to treat tumours. In the case of
Betalutin®-based treatment, which to date has demonstrated an encouraging
clinical profile, such combination strategies could further enhance its
potential to become an important option for NHL patients."

Abstract 2574

Abstract title:           The Dual Cell Cycle Kinase Inhibitor JNJ-7706621
Reverses Resistance to CD37 Targeted Radioimmunotherapy in Activated B Cell like
Diffuse Large B Cell Lymphoma Cell Lines

Authors:                 G.E. Rødland et al.

Session Name:        605. Molecular Pharmacology, Drug Resistance-Lymphoid and
Other Diseases: Poster II

Date:                      Sunday, 8 December 2019

Presentation Time:   6:00 PM - 8:00 PM Eastern time

Location:                 Orange County Convention Center, Hall B

The abstract is available at
https://ash.confex.com/ash/2019/webprogram/Paper123287.html and the poster will
be published on the Nordic Nanovector website to coincide with the session.

About ASH

The ASH annual meeting is the premier event for scientific exchange in the field
of haematology, attracting more than 20,000 attendees from all over the world.
Typically, more than 5,000 scientific abstracts are submitted each year, and
more than 3,000 abstracts are accepted for oral and poster presentations through
an extensive peer review process. https://hematology.org/Annual-Meeting/

For further information, please contact:

IR enquiries

Malene Brondberg, VP Investor Relations and Corporate Communications

Cell: +44 7561 431 762

Email: ir@nordicnanovector.com

Media Enquiries

Mark Swallow/David Dible (Citigate Dewe Rogerson)

Tel: +44 207 638 9571

Email: nordicnanovector@citigatedewerogerson.com

About Nordic Nanovector:

Nordic Nanovector is committed to develop and deliver innovative therapies to
patients to address major unmet medical needs and advance cancer care. The
Company aspires to become a leader in the development of targeted therapies for
haematological cancers.

Nordic Nanovector's lead clinical-stage candidate is Betalutin®, a novel CD37
-targeting radioimmunotherapy designed to advance the treatment of non-Hodgkin's
lymphoma (NHL). NHL is an indication with substantial unmet medical need,
representing a growing market forecast to be worth nearly USD 29 billion by
2026. Nordic Nanovector intends to retain marketing rights and to actively
participate in the commercialisation of Betalutin® in core markets.

Further information can be found at www.nordicnanovector.com.

Forward-looking statements

This press release contains certain forward-looking statements.  These
statements are based on management's current expectations and are subject to
uncertainty and changes in circumstances, since they relate to events and depend
on circumstances that will occur in the future and which, by their nature, will
have an impact on Nordic Nanovector's business, financial condition and results
of operations. The terms "anticipates", "assumes", "believes", "can", "could",
"estimates", "expects", "forecasts", "intends", "may", "might", "plans",
"should", "projects", "targets", "will", "would" or, in each case, their
negative, or other variations or comparable terminology are used to identify
forward-looking statements. These forward-looking statements are not historic
facts. There are a number of factors that could cause actual results and
developments to differ materially from those expressed or implied in the forward
-looking statements. Factors that could cause these differences include, but are
not limited to, risks associated with implementation of Nordic Nanovector's
strategy, risks and uncertainties associated with the development and/or
approval of Nordic Nanovector's product candidates, ongoing and future clinical
trials and expected trial results, the ability to commercialise Betalutin®,
technology changes and new products in Nordic Nanovector's potential market and
industry, Nordic Nanovector's freedom to operate (competitors patents) in
respect of the products it develops, the ability to develop new products and
enhance existing products, the impact of competition, changes in general economy
and industry conditions, and legislative, regulatory and political factors. No
assurance can be given that such expectations will prove to have been correct.
Nordic Nanovector disclaims any obligation to update or revise any forward
-looking statements, whether as a result of new information, future events or
otherwise.

This information is subject to a duty of disclosure pursuant to Sections 4-2 and
5-12 of the Securities Trading Act.